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Abstract
Background: Native T1 mapping is a cardiovascular magnetic resonance (CMR) technique that associates with markers of
fibrosis and strain in hemodialysis patients. The reproducibility of T1 mapping in hemodialysis patients, prone to changes in
fluid status, is unknown. Accurate quantification of myocardial fibrosis in this population has prognostic potential.
Methods: Using 3 Tesla CMR, we report the results of 1) the inter-study, inter-observer and intra-observer reproducibility
of native T1 mapping in 10 hemodialysis patients; 2) inter-study reproducibility of left ventricular (LV) structure and
function in 10 hemodialysis patients; 3) the agreement of native T1 map and native T1 phantom analyses between two
centres in 20 hemodialysis patients; 4) the effect of changes in markers of fluid status on native T1 values in 10
hemodialysis patients.
Results: Inter-study, inter-observer and intra-observer variability of native T1 mapping were excellent with co-efficients of
variation (CoV) of 0.7, 0.3 and 0.4% respectively. Inter-study CoV for LV structure and function were: LV mass = 1%; ejection
fraction = 1.1%; LV end-diastolic volume = 5.2%; LV end-systolic volume = 5.6%. Inter-centre variability of analysis
techniques were excellent with CoV for basal and mid-native T1 slices between 0.8–1.2%. Phantom analyses showed
comparable native T1 times between centres, despite different scanners and acquisition sequences (centre 1: 1192.7 ± 7.
5 ms, centre 2: 1205.5 ± 5 ms). For the 10 patients who underwent inter-study testing, change in body weight (Δweight)
between scans correlated with change in LV end-diastolic volume (ΔLVEDV) (r = 0.682;P = 0.03) representing altered fluid
status between scans. There were no correlations between change in native T1 between scans (ΔT1) and ΔLVEDV or
Δweight (P > 0.6). Linear regression confirmed ΔT1 was unaffected by ΔLVEDV or Δweight (P > 0.59).
Conclusions: Myocardial native T1 is reproducible in HD patients and unaffected by changes in fluid status at the levels we
observed. Native T1 mapping is a potential imaging biomarker for myocardial fibrosis in patients with end-stage renal disease.
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Background
There is an increased risk of cardiovascular (CV) mortality
in chronic kidney disease (CKD), and end stage renal
disease (ESRD) populations [1]. This increased risk can be
attributed to the stereotyped changes that lead to the
development of uremic cardiomyopathy and include, left
ventricular (LV) hypertrophy, LV dilatation and myocardial
fibrosis within the extracellular matrix [2]. To date, LV
mass is the most commonly used surrogate end-point of
mortality in clinical trials [3], as observational studies of
HD patients have shown LV mass is good predictor of CV
outcomes [4]. However, a recent systematic review and
meta-analysis in patients of all stages of CKD suggested that
there is no clear association between intervention-induced
LV mass reduction and mortality [5]. Novel imaging bio-
markers that can robustly and reliably measure pathological
CV changes that link strongly to outcomes are required.
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Post-mortem studies of patients with CKD and ESRD on
hemodiaysis (HD) demonstrate that uremia is a highly
significant, independent determinant of extent of myocar-
dial fibrosis [6]. Furthermore endomyocardial biopsy stud-
ies have shown that extent of myocardial fibrosis is the only
independent predictor of death (mean follow-up period
3.1 years) for these patents [7]. As degree of myocardial
fibrosis is the strongest predictor of increased CV mortality,
defining a reliable measure of myocardial fibrosis in HD
patients is a priority.
Cardiovascular Magnetic Resonance (CMR) with Late
Gadolinium Enhancement (LGE) is an imaging biomarker
used to assess myocardial fibrosis in many populations.
Whilst gadolinium based contrast agents have previously
been used to assess cardiac disease in HD patients [8] this
is no longer possible due to the rare, but serious complica-
tion of nephrogenic systemic fibrosis [9]. Moreover, whilst
LGE is a sensitive and reproducible way of assessing focal
myocardial fibrosis, there are limitations in using gadolin-
ium to assess diffuse myocardial fibrosis due to the reliance
of the technique on demonstrating a difference between
signal intensity of normal and fibrotic myocardial tissue
[10]. Native T1 mapping is a novel, non-contrast CMR
technique that correlates well with biopsy measured
myocardial fibrosis in aortic stenosis [11, 12] and can
differentiate patients with hypertrophic cardiomyopathy
from hypertensive cardiac disease [13]. The inter-study re-
peatability and inter-observer variability of native T1 map-
ping has been shown to be very good in patients with
aortic stenosis [14], patients with LV hypertrophy or dilated
cardiomyopathy [15] and patients with Anderson-Fabry dis-
ease [16]. Myocardial native T1 times have been shown to
be significantly higher in HD patients compared to control
subjects [17, 18] and to associate with circulating markers
of cardiac disease [17] and measures of myocardial systolic
strain [18], but the reproducibility of native T1 mapping
has not been assessed in HD patients who are prone to
shifts in extracellular volume. Native T1 times are pro-
longed with increasing water content of tissue and the pres-
ence of intermittent myocardial edema from alterations in
fluid status may in theory affect native T1 time confound-
ing results and reducing native T1 time reproducibility.
Concerns remain about the use of this technique to assess
myocardial fibrosis in patients with ESRD on HD, who are
subject to significant changes in fluid status and who may
potentially have intermittent myocardial oedema [19].
In this study we aim to assess the reproducibility and
reliability of native T1 mapping in patients with ESRD
on HD by assessing: i) the inter-study, inter-observer
and intra-observer variability of native T1 times in HD
patients at 3 Tesla (3 T); ii) the associations between
changes in markers of fluid status and changes in native
T1 times to assess the effect of fluid status on native T1
times; iii) the inter-centre reproducibility of native T1
values between two UK cardio-renal imaging centres,
comparing analysis techniques of native T1 maps and
native T1 values with ‘phantom’ analysis [20].
Methods
Patients from centre 1 were recruited as a part of the
CYCYLE-HD study (ISRCTN 11299707) [21]. The study
was given ethical approval by the NHS Research Ethics
Committee East Midlands (Northampton; REC ref: 14/EM/
1190). Patients from centre 2 were recruited as part of the
observational cardiac uraemic fibrosis detection in dialysis
patients study (CUDDLE study ISCRTN99591655). The
study was approved by the West of Scotland Ethics com-
mittee (WoS 13/WS/0301). All participants gave written
and informed consent.
Inter-study reproducibility, inter-observer and
intra-observer variability (centre 1)
Ten patients underwent a repeat CMR scan within 2 weeks
of their initial scan. Patients receive dialysis three times per
week on either a Monday, Wednesday, Friday, or a Tuesday,
Thursday, Saturday. This means that there is a two-day break
between dialysis once a week, commonly referred to as ‘the
long break’. Study patients were all scanned on a non-dialysis
day within 24 h after their last dialysis and never during the
long-break. The same CMR protocol was used for each scan
(see below). We report the inter-study reproducibility of LV
volumes, mass and of the mid-ventricular native T1 paramet-
ric mapping. Analysis of inter-study scans was conducted by
a single, blinded, observer. Inter-observer variability of was
conducted by 2 blinded observers on 10 native T1 maps in-
dependently from one another. Intra-observer variability was
conducted by a single blinded observer.
Inter-centre reproducibility (centre 1 and centre 2)
The inter-observer variability of native T1 map analysis
techniques between 2 UK cardio-renal imaging centres was
assessed. The CMR scanners, native T1 mapping sequences
and analysis techniques of centre 1 and centre2 were
different (see below). Ten basal and 10 mid-ventricular na-
tive T1 scans acquired at centre 1 were analysed by a
blinded observer at centre 2, using the analysis technique
of centre 2 and compared to the results of the analysis of
the same scans analysed at centre 1. Conversely 10 basal
and mid-ventricular native T1 scans acquired at centre 2
were analysed by a blinded observer at centre 1, using the
analysis technique of centre 1 and compared to the results
of the analysis of the same scans analysed at centre 2. We
also undertook native T1 phantom analysis at both centres.
Phantom analyses were undertaken at centre 1 and centre
2 as part of the international, multi-centre T1MES project
[20]. Phantom images recorded at a heart rate of approxi-
mately 70 beats per minute were obtained and compared.
The phantoms were scanned once at each centre and the
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images were analysed at centre 2. Uniform regions of inter-
est within each relevant phantom area were determined
using semi-automated user defined border delineation soft-
ware (Siemens Argus Analysis Software, Siemens, Erlangen,
Germany). The values obtained and their standard devia-
tions were then recorded.
CMR protocols
The CMR protocols at centres 1 and 2 were pre-defined in
the CYCLE-HD and CUDDLE studies respectively. Differ-
ences in scan parameters are due to local expertise in gaining
the highest quality images possible with the fewest number
of artefacts.
CMR protocol centre 1
All patients were imaged on a 3 T CMR platform (Skyra,
Siemens Medical Imaging, Erlangen, Germany) using an
18-channel phased-array anterior coil. Patients were
scanned on non-dialysis days, but not after the long-break.
The CMR protocols for acquiring cine imaging and native
T1 maps were as previously described [18], conforming to
internationally recognized standards [22]. Electrographic
gated breath-hold steady-state free procession long-axis
cine images in 2, 3 and 4 chamber views were acquired.
Short axis cine images covering the entire left ventricle
were taken at 8 mm slice thickness, 2 mm gap, field of view
300 x 400 mm, matrix 208 x 256, repetition time 2.9 ms,
echo time 1.2 ms, flip angle 64-790, temporal resolution
<50 ms, with 30 phases per cardiac cycle, in-plane image
resolution 1.1 x 1.5 mm to 1.3 x 1.7 mm.
T1 imaging parameters included acquisition of basal and
mid T1 maps in 2 LV short-axis slices using the modified
look-locker inversion recovery (MOLLI) sequence. Images
were acquired using free-breathing with motion correction
(MOCO), ECG-gated single-shot MOLLI sequence [23],
with 3(3)3(3)5 sampling pattern and the following typical
parameters: slice thickness 8.0 mm, field of view 300 ×
400 mm, flip angle 50°, minimum TI 120 ms, inversion-
time increment 80 ms. MOLLI maps of the left ventricle
were acquired at basal and mid-short-axis. The MOLLI se-
quence was chosen due to the technique’s excellent inter
and intra-observer variability at 3 T [24] and because of
local expertise [14]. To minimize artefacts, acquisition was
performed with the region of interest at isocentre, a small
shim volume was applied around the myocardium, a large
field of view (400 mm) was used, and imaging was repeated
after changing the phase-encoding direction or resonance
offset frequency if artefacts persisted.
CMR protocol centre 2
All participants were scanned on a 3 T CMR platform
(Siemens Magnetom PRISMA, Siemens Medical Imaging,
Erlangen, Germany) using a 16 channel phased-array anter-
ior coil. As at centre 1 CMR imaging was performed on a
non-dialysis day. Image acquisition was ECG-gated and as
previously described [17]. T1 imaging parameters included
acquisition of basal and mid T1 maps in 2 LV short-axis
slices using a MOLLI sequence. Typical acquisition param-
eters were: slice thickness 6.0 mm, field of view 360 x
307 mm, flip angle 35°, minimum T1 180 ms, inversion-
time increment 80 ms, repetition time 267.84 ms, band-
width 1085 Hertz/pixel.
CMR scan analysis centre 1
All scans were analysed offline by a single blinded observer
using the software package CMR42 (Circle Cardiovascular
Imaging, Calgary, Alberta, Canada). Image quality was
assessed as being excellent, good, acceptable or poor. LV vol-
umes and mass were quantified as previously described with
epicardial and endocardial short axis cines at end- diastole
and end-systole [25]. The native T1 parametric map derived
from MOCO MOLLI images was used to assess native T1
signal due to superior intra and inter-observer variability as
described by our group compared to analysing the MOCO
series [14]. Using the CMR42 T1 characterization module,
endocardial and epicardial borders were drawn on basal and
mid-ventricular T1 parametric maps for each patient, with
care taken to allow adequate margins of separation from tis-
sue interfaces such as between the blood pool or epicardial
fat and myocardium. The anterior right ventricular insertion
point was then defined to automatically divide the basal-
ventricular and mid-ventricular slices into 6 segments each
according to the American Heart Association 16-segment
model (Fig. 1). Each individual segment was assessed for the
presence or absence of susceptibility and motion artefacts.
After removal of any segments affected by artefact, an aver-
age T1 time for the whole of the myocardium was calculated
from the mean of remaining segments.
CMR scan analysis centre 2
All scans were analysed offline by a single blinded observer
using Siemens Argus Analysis software (Siemens, Erlangen,
Germany). The image analysis technique was as previously
described [17]. LV contours were defined on raw T1 images
(the first image, with the lowest inversion time, allowing for
optimal tissue blood-pool contrast) and copied into the
parametric T1 maps [26, 27]. Using the anterior right ven-
tricular insertion point as a reference, basal and mid T1
maps were segmented according to the American Heart
Association 16-segment model and regions of interest were
delineated by user-defined border delineation. The regions
of interest were standardized to be of similar size and
shape. T1 times were measured in each of the 6 basal and 6
mid segments as well as the blood pool, with care taken to
delineate regions of interest with adequate margins of sep-
aration from tissue interfaces such as between the blood
pool or epicardial fat and myocardium (Fig. 1). Each indi-
vidual segment was assessed for the presence or absence of
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susceptibility and motion artefacts. After removal of any
segments affected by artefact, an average T1 time for the
whole of the myocardium was calculated from the mean of
remaining segments.
Statistical analysis
Statistical analysis were undertaken using SPSS-22 software
(Statistical Package for the Social Sciences, Chicago, IL, USA)
and Graphpad Prism version 6.04 (GraphPad Software, Inc.,
La Jolla, CA, USA). Normality was assessed using the
Shapiro–Wilk test, histograms, and Q–Q plots. Normally
distributed data are expressed as mean ± standard deviation
and non-normally distributed data are expressed as median
(interquartile range). Interstudy and inter-observer variability
for subjects undergoing test-retest scans were compared
using paired t-tests, co-efficients of variation and the Bland-
Altmann method [28]. Inter-centre differences between sub-
ject demographics and native T1 values were assessed with
independent sample t-tests or Mann-Whitney U tests for
normally and non-normally distributed data respectively.
Chi-squared tests and Fishers exact tests were used to assess
for differences between nominal variables and are expressed
as ‘count’ (%). Correlations between variables were assessed
using Pearson’s and Spearman’s-rank analysis for normally
and non-normally distributed data respectively.
Sample size justification
A paired t-test sample size calculation was undertaken for
the native T1 test-rest study, using the native T1 values from
a previous study by our group conducted on the same 3 T
MRI scanner (Skyra, Siemens Medical Imaging, Erlangen,
Germany) [14]. To detect a 2.5% difference in native T1
times between test-retest scans (27 ms) with 90% power re-
quires 8 patients to undergo test-retest scans. Ten patients
were therefore recruited to undergo test-retest scans.
Results
The demographic data for all patients from both centres are
shown in Table 1. There were no statistically significant
differences between the demographics of the groups. There
was a trend towards longer dialysis vintage in participants
Fig. 1 a: Native T1 map analysis of a mid-ventricular slice with software package CMR42 at centre 1. Endocardial (red line) and epicardial (green
line) contouring on native T1 parametric map. Segments (1–6) are calculated from defining the RV insertion point (arrow). b: Typical segmentation
of a basal native T1 map site from centre 2. 6 discrete regions of interest drawn within the myocardium for each segment
Table 1 Demographic details from both study centres
Variable Centre 1 (n = 10) Centre 2 (n = 10)
Age (Years) 57.8 ± 15 58 ± 13.5
Male (%) 8 (80%) 7 (70%)
HR (bpm) 76 ± 14 68 ± 11.6
SBP (mmHg) 143 ± 33 143 ± 19
DBP (mmHg) 80. ± 15 72 ± 13
Dialysis Vintage (Months) 26 ± 26.2 9 ± 3.9
Past Medical and Drug History
HTN (n,%) 8 (80%) 6 (60%)
Diabetes (n,%) 3 (30%) 2 (20%)
Previous MI (n,%) 1 (10%) 2 (20%)
CAD (n,%) 3 (30%) 3 (30%)
PVD (n,%) 0 (0%) 1 (10%)
ACEi (n,%) 3 (30%) 1 (10%)
ARB (n%) 1 (10%) 0 (0%)
Diuretic (n,%) 1 (10%) 2 (20%)
Beta Blocker (n,%)* 4 (40%) 7 (70%)
Statin (n,%) 4 (40%) 5 (50%)
Calcium Channel Blocker (n,%) 3 (30%) 2 (20%)
Number of antihypertensives 0.96 ± 0.9 1.1 ± 0.9
Mean values with standard deviation expressed as n ± SD. N, % = Chi-squared
+%. No significant differences were observed between any baseline
demographic details
bpm beats per minute, ACEi angiotensin converting enzyme inhibitor, ARB
angiotensin receptor blocker, CAD coronary artery disease, DBP diastolic blood
pressure, HR heart rate, HTN hypertension, MI myocardial infarction, PVD
peripheral vascular disease, SBP systolic blood pressure
*statistically significant difference between groups (P<0.05)
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from centre 1 compared to those in centre 2, but these
difference did not reach statistical significance. There were
no differences between the basal or the mid-ventricular na-
tive T1 times for HD patients between centre 1 and centre 2
respectively (basal T1 1280.5 ms ± 36.6 vs 1276.3 ms ± 32.3,
P= 0.62 and mid T1 1282.6 ms ± 38.1 vs 1283.4 ± 39.3, P =
0.42). All scans were analysable and included in the analysis.
Inter-study reproducibility of LV masses and volumes
The mean interval between scans for patients undergoing
test-retest inter-study reproducibility at centre 1 was 7 ±
4 days. Image quality was either good (n= 4) or excellent (n
= 16) and of sufficient quality for quantitative analysis. The
inter-study reproducibility, including coefficients of variation
(CoV), bias and limits of agreement for LV mass, LVEDV,
LVESV and LVEF are shown in Table 2. Bland-Altman plots
did not show evidence of systematic bias, with all data points
within 95% confidence intervals (Fig. 2). Interstudy mean
difference and 95% confidence intervals of LVEDVand weight
were 11.79 ml (5.6,18.0) and 0.5 kg (0.1,0.8) respectively.
There was a significant correlation between change in LVEDV
(ΔLVEDV) and change in weight (Δweight) between scans (r
= 0.682, P= 0.03), but no association was found between
change in LV mass (ΔLVMass) and ΔLVEDV or Δweight (r=
0.16, P= 0.67 and r= 0.12, P= 0.73 respectively) (Fig. 3).
Inter-study reproducibility, inter-observer and
intra-observer variability of mid-ventricular native T1
Six out of 120 native T1 segments from mid-ventricular na-
tive T1 parametric maps were excluded from analysis due to
artefact. The same segments were excluded from analysis by
the two readers in the inter-observer analysis (one segment
from interventricular septum and five from the lateral wall).
The inter-study reproducibility, inter-observer and intra-
observer variability of mid-ventricular native T1 values, in-
cluding CoV, bias and limits of agreement for mid-LV native
T1 values are shown in Table 2. Bland-Altman plots did not
show evidence of any systematic bias, with all data points
within 95% confidence intervals (Fig. 2). There was no
significant correlation between change in mid-ventricular
native T1 (ΔT1) or change in LVEDV (ΔLVEDV) and
change in weight (Δweight) between scans (r= -0.14, P = 0.7
and r = 0.2, P= 0.6, respectively) (Fig. 4). Linear regression
confirmed ΔT1 was unaffected by both ΔLVEDV and
Δweight (adj R2 = 0.1, P= 0.71 and adj R2 = 0.08, P = 0.59).
Based on these results, to detect a 2.5% difference in native
T1 values with 90% power would require 13 patients and to
detect a 5% difference in native T1 values with 90% power
would require 5 patients (alpha error = 0.05 for both).
Inter-centre measurement variability of basal and
mid-ventricular native T1
Twenty-five out of 240 native T1 segments were excluded
from analysis due to artefact (9 segments were excluded from
the interventricular septum and 16 from the later wall). The
two readers agreed on the analysability of 220/240 segments
reviewed (91.7%). The inter-centre variability of native T1
analysis techniques of basal and mid-ventricular native T1
values, including CoV, bias and limits of agreement are
shown in Table 3. Bland-Altman plots did not show evidence
of systematic bias (Additional file 1: Appendix 1), although
single data points fell just outside the 95% confidence inter-
vals for mid-ventricular native T1 of centre 1 and for basal-
ventricular and mid-ventricular native T1 for centre 2.
T1 values of standard phantom between centres
Excellent agreement was seen for the phantom results
obtained at both centres with no clinically relevant dif-
ferences between scanners. Allowing for standard devia-
tions, the phantom considered representative of a typical
myocardial tissue T1 time, gave very similar T1 values at
both sites (centre 1: 1192.7 ± 7.5 ms, centre 2: 1205.5 ±
5 ms). For the phantom blood pool T1 times obtained
Table 2 Interstudy reproducibility of LV mass, volumes and mid-ventricular native T1 values and Inter-observer and intra-observer
variability of mid-ventricular native T1 values
Parameter Study 1 Study 2 CoV BIAS ± SD Difference BA Limits of Agreement
Inter-study reproducibility
LV Mass (diastolic) (g) 95.2 ± 22.0 95.5 ± 22.7 1.0% -0.3 ± 1.96 -4.5–3.5
LVEDV (ml) 139.3 ± 21.0 138.5 ± 27.8 5.2% 0.8 ± 15.2 -28.9–30.5
LVESV (ml) 64.3 ± 16.3 64.2 ± 19.7 5.6% 0.1 ± 7.6 -14.8–15
LVEF (%) 54.3 ± 7.2 54.4 ± 6.8 1.1% -0.1 ± 1.3 -2.6–2.4
Mid-ventricular native T1 (ms) 1267.8 ± 35.4 1270.7 ± 30.5 0.7% -2.9 ± 17.5 -37.2–31.3
Inter-observer variability
Mid-ventricular native T1 (ms) 1267.6 ± 35.4 1271 ± 34.8 0.3% -3.4 ± 6.2 -15.6–8.8
Intra-observer variability
Mid-ventricular native T1 (ms) 1267 ± 34.3 1266 ± 35.5 0.4% 0.66 ± 11.7 -22.3–23.7
Mean values with standard deviation expressed as n ± SD
BA Bland-Altman, LV left ventricular, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVEF left ventricular ejection fraction
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were again equivalent at each centre: (centre 1: 1899.2 ±
6.9 ms, centre 2: 1907.9 ± 10.7 ms).
Discussion
In this study we have shown, for the first time in patients
with ESRD on HD, that the reproducibility of native T1
values are excellent. The reproducibility values for T1
mapping using the MOLLI sequence compare favourably
with those previously reported. Previous CoVs for inter-
study reproducibility have been between 1.5 and 8.4%,
[14–16, 29] compared with 0.7% in this report. As previ-
ously described, native T1 is related to water content of
the relevant tissue [30] and the finding in this study that
ΔT1 between test-re-test scans was unrelated to changes
in fluid status suggests that changes in fluid status at the
levels we have seen do not directly affect native T1 values
in HD patients, although we accept that this study is only
in 10 patients. Whilst the absolute changes in inter-study
fluid status that we report are not large, they are the types
of fluctuations in fluid you would expect to see in HD pa-
tients scanned on a non-dialysis day on week apart and
therefore clinically relevant. This is a crucial observation
in defining the reliability of T1 time as a potential measure
of myocardial fibrosis in this patient group.
We have demonstrated that standardization of native T1
mapping analysis between centres is eminently possible.
The agreement between the analysis techniques of centres
is encouraging. Both techniques define segmental native T1
values for basal- and mid-ventricular slices as per the
American Heart Association model (Fig. 1), with the aver-
age of these segments taken to be the mean native T1 for
each slice. When areas of artefact are identified, affected
segments can be excluded with the mean native T1 calcu-
lated from remaining unaffected segments. This way of
assessing native T1 is likely to be more reproducible than
alternative methods, where single regions of interest are
drawn in the inter-ventricular septum [31]. Such methods
are prone to sampling differences in native T1 times de-
pending on where the region of interest is drawn. We have
previously demonstrated that septal native T1 is signifi-
cantly higher than non-septal native T1 in HD patients
[18]. Moreover, a recent paper by Rauhalammi et al showed
that native T1 values are significantly higher in the inter-
ventricular septum of health volunteer patients than non-
septal myocardium [27] so analysis techniques that measure
only the interventricular septal native T1 cannot be thought
of as equivalent to mean circumferential ventricular native
T1 values. The phantom analysis conducted at centre 1 and
Fig. 2 Bland-Altman plots for: a: Inter-study reproducibility left ventricular mass, b: Inter-study reproducibility left ventricular end-diastolic volume,
c: Inter-study reproducibility left ventricular ejection fraction, d: Inter-study reproducibility mid-ventricular native T1, e: inter-observer variability of
mid-ventricular native T1 and f: intra-observer variability of mid-ventricular native T1
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centre 2 confirmed the scanners and scan sequences at the
different centres gave very similar results, with the differ-
ences in absolute values being clinically irrelevant. The
mean basal- and mid-ventricular native T1 values between
the two centres were virtually identical. Given that subjects
from both centres were well matched in terms of demog-
raphy and medical co-morbidity, it appears that the native
T1 values generated at both centres are commensurate with
each other. It should be noted that both centres used
Siemens 3 T CMR scanners and whilst they were not the
same model scanner, inter-vendor comparisons of myocar-
dial native T1 values in HD patients are required. Ideally
assessment of the reproducibility of native T1 times at dif-
ferent field strengths and between vendors and centres
should also be carried out.
Although native T1 time has been shown to correlate well
with histological levels of myocardial fibrosis in diseases of
pressure overload [12] we still do not have histological
Fig. 3 Relationships between measures of fluid status between
scans and LV mass. a: Significant correlation between Delta LVEDV
and Delta weight. b: No relationship between Delta LVEDV and
Delta LV Mass or c: between Delta Weight and Delta LV mass. LV,
left ventricular; LVEDV, Left ventricular end-diastolic volume
Fig. 4 Relationships between changes in native T1 and changes in
measures of fluid status. a: No correlation between delta native T1 and
delta LVEDV. b: No relationship between delta native T1 and delta weight
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confirmation that this is the case for HD patients; indeed low
grade inflammation may increase native T1 [32]. Low grade
inflammation is known to be a feature of CKD and for pa-
tients with ESRD on HD [33], so histological studies are re-
quired to confirm increased T1 times are due to myocardial
fibrosis and not low grade inflammation or an additional dis-
ease process such as amyloidosis [34]. Whilst our results sug-
gest inter-compartmental fluid shifts do not affect native T1
values, further, confirmatory studies should be considered, in-
cluding studies that look at the acute effects of HD and ultra-
filtration on native T1 values.
The inter-study reproducibility of traditional CMR
measures of LV structure and function, including LV
mass, LVEDV and LVEF were also excellent as has been
shown previously for patients with ESRD [35]. The re-
producibility of LV mass is particularly important as LV
mass is known to be overestimated when imaged with
echocardiography [36]. These findings confirm previous
studies in HD patients showing conservation of meas-
urement of LV mass with CMR in patients with differing
LVEDV’s and fluid and loading status [35].
In 2011, Sado et al outlined a framework for development
of imaging techniques to measure myocardial fibrosis, to
ensure the robustness of the techniques [37]. They sug-
gested that to be considered a reliable imaging biomarker
of myocardial fibrosis, techniques should: detect changes in
established disease states compared with controls; correlate
with cardiac markers fibrosis (e.g., diastolic function, LVH);
correlate with blood biomarkers of cardiac fibrosis; be able
to track changes over time; be standardized in the way they
are carried out (inter-vendor/inter-centre); be proven to
compare closely with histological specimens from human
subjects; and changes in the imaging biomarker should
track changes in the disease after treatment. Work by our
respective groups has already shown that native T1 values
are higher than healthy and co-morbidity matched controls
[17, 18]. Rutherford et al demonstrated that global native
T1 values in HD correlate with LV mass indices (r = 0.452,
P = 0.008), and that septal T1 values correlate with pre-
dialysis high-sensitive troponin T (r = 0.397, P = 0.027) [17].
In addition to this, Graham-Brown et al showed that native
T1 values correlate with measures of global circumferential
and longitudinal strain (r = 0.41, P = 0.002, r = 0.55, P <
0.001) and septal native T1 correlated with septal systolic
strain (r = 0.46, P < 0.001) [18].
Following the framework outlined by Sado et al, histo-
logical confirmation of the relationship between myocardial
fibrosis and native T1 mapping now appears to be the final
step required before longitudinal and interventional studies
can be undertaken to define whether native T1 mapping is
able to: track progression of myocardial fibrosis over time;
assess how baseline or changes in native T1 values relate to
outcomes; whether interventions that attempt to modify/im-
prove fibrosis are measurable by native T1 mapping; and
whether this modification improves outcomes for patients.
The excellent reproducibility of native T1 mapping makes it
a biomarker with great potential for the measurement of
myocardial fibrosis in HD patients. Based on the results we
have presented, only small numbers of patients would be re-
quired to adequately power interventional clinical trials that
seek to reduce myocardial fibrosis. Whilst historically LV
mass has been the surrogate end-point for clinical trial work
that sought to improve CV outcomes, a recent systematic
review and meta-analysis has called into question whether
interventions that improve LV mass actually improve out-
comes for patients with CKD and ESRD [5]. It should be
noted that the neutral result of this meta-analysis might be
due to inadequate power. Post-mortem histo-pathological
studies have shown us that extent of myocardial fibrosis is
the best predictor of outcome in patients with CKD and
ESRD [6] and there is evidence in animal models, humans
and even HD patients that regression of LVH is accompan-
ied by reductions in measures of myocardial fibrosis [38–
41]. Given that multiple studies have suggested that redu-
cing LV mass improves outcomes for patients with ESRD
[42], it could be that previous trials that have shown reduc-
tions in LV mass have actually just reflected a crude measure
of a reduction in myocardial fibrosis content and this has
led to the conflicting results about the importance of LV
mass reduction and CV risk that has recently been reported.
Given the central association between fibrosis, LVH, mor-
bidity and mortality in HD patients, being able to reliably
measure diffuse myocardial fibrosis is crucial to understand-
ing its potential as a research and clinical end point.
Table 3 Inter-centre variability of basal and mid-ventricular native T1 analysis techniques
Parameter Centre 1 analysis Centre 2 analysis CoV Bias ± SD Difference BA Limits of Agreement
Centre 1 native T1 images
Basal native T1 (ms) 1283.8 ± 38.7 1281.4 ± 39.6 0.8% 2.4 ± 21.5 -39.7–44.6
Mid native T1 (ms) 1281.3 ± 39.6 1279.8 ± 35.6 1.2% 1.5 ± 31.2 -59.7–62.6
Centre 2 native T1 images
Basal native T1 (ms) 1290.4 ± 36.7 1276.4 ± 42.5 0.8% 14.1 ± 17.2 -19.7–47.8
Mid native T1 (ms) 1281.3 ± 31.6 1271.3 ± 33.9 0.9% 10 ± 23.1 -35–55.2
Mean values with standard deviation expressed as n ± SD
BA Bland-Altman
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Conclusion
Native T1 mapping is an extremely reproducible technique
in HD patients. Native T1 times seem to be unaffected by
the changes in fluid status to which HD patients are prone.
Further work is required to determine whether native myo-
cardial T1 is related to prognosis in ESRD and whether in-
terventions that reduce T1 are associated with improved
outcomes.
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